Overall, AKT inhibitors have shown a lack of correlation between PI3K/AKT pathway alterations and efficacy of AKT inhibitors from HR+ BC patients with limited data available on HER2+ and a positive trend in TNBC patients. The gene discussed is PIK3CA; the disease is breast cancer.